Healthcare [ 12/13 ] | Medical Instruments & Supplies [ 135/164 ]
NASDAQ | Common Stock
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
It also offers ELISA test kits; and chromatography resins under the CaptivA brand.
In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths.
Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands.
The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations.
Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands.
The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 1, 24 | 0.28 Decreased by -56.25% | 0.30 Decreased by -6.67% |
| Feb 21, 24 | 0.33 Decreased by -51.47% | 0.33 |
| Oct 31, 23 | 0.23 Decreased by -70.13% | 0.17 Increased by +35.29% |
| Aug 2, 23 | 0.53 Decreased by -41.76% | 0.48 Increased by +10.42% |
| May 2, 23 | 0.64 Decreased by -30.43% | 0.59 Increased by +8.47% |
| Feb 22, 23 | 0.68 Decreased by -16.05% | 0.58 Increased by +17.24% |
| Nov 1, 22 | 0.77 Decreased by -1.28% | 0.68 Increased by +13.24% |
| Aug 2, 22 | 0.91 Increased by +15.19% | 0.72 Increased by +26.39% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 151.35 M Decreased by -17.14% | 2.09 M Decreased by -92.74% | Increased by +1.38% Decreased by -91.23% |
| Dec 31, 23 | 155.74 M Decreased by -16.61% | -25.49 M Decreased by -152.31% | Decreased by -16.37% Decreased by -162.72% |
| Sep 30, 23 | 141.19 M Decreased by -29.66% | 18.17 M Decreased by -55.03% | Increased by +12.87% Decreased by -36.06% |
| Jun 30, 23 | 159.17 M Decreased by -23.34% | 20.06 M Decreased by -59.76% | Increased by +12.61% Decreased by -47.51% |
| Mar 31, 23 | 182.66 M Decreased by -11.50% | 28.83 M Decreased by -38.61% | Increased by +15.78% Decreased by -30.64% |
| Dec 31, 22 | 186.76 M Increased by +0.13% | 48.73 M Increased by +67.40% | Increased by +26.09% Increased by +67.18% |
| Sep 30, 22 | 200.74 M Increased by +12.64% | 40.41 M Increased by +20.62% | Increased by +20.13% Increased by +7.08% |
| Jun 30, 22 | 207.63 M Increased by +27.41% | 49.86 M Increased by +37.61% | Increased by +24.01% Increased by +8.00% |